Physician profile
Donna Kolar
NPI 1174640932
$7,390.04
in general payments reported to CMS, 2019-2025
37 companies · $3,137 in 2025
The $3,137 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $590 · 2021: $1,190 · 2022: $565 · 2023: $985 · 2024: $289 · 2025: $3,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $343.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,000.00 | 2025 | |
| Abbvie INC. | $941.07 | 2019-2023 | |
| Astellas Pharma US INC | $754.91 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $554.75 | 2021-2025 | |
| Exeltis, USA INC. | $468.52 | 2019-2025 | Slynd, Twirla, Nuvessa |
| Coopersurgical, INC. | $332.69 | 2019-2022 | |
| Agile Therapeutics, INC. | $198.86 | 2021-2022 | |
| Millicent US INC | $197.92 | 2022-2024 | Intrarosa |
| Hologic Sales and Service, LLC | $194.98 | 2020-2023 | Acessa Provu System |
| Evofem Biosciences, INC. | $163.97 | 2020-2022 | |
| Lupin INC. | $135.54 | 2019-2021 | |
| Therapeuticsmd, INC. | $135.44 | 2019-2022 | |
| Medical Device Business Services, INC. | $130.17 | 2025 | Dermabond |
| Pfizer INC. | $122.23 | 2019-2024 | |
| Aspira Women'S Health INC | $107.55 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $106.55 | 2022-2024 | Nexplanon, Nuvaring |
| Virtus Pharmaceuticals LLC | $101.23 | 2021 | |
| Amag Pharmaceuticals, INC. | $96.50 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.49 | 2019-2025 | |
| Ascend Therapeutics US, LLC | $61.55 | 2020-2023 | |
| Allergan, INC. | $53.75 | 2019-2020 | |
| Ethicon US, LLC | $51.99 | 2024-2025 | Vistaseal, Stratafix, Enseal |
| Minerva Surgical, INC | $49.96 | 2023 | |
| Avion Pharmaceuticals | $47.35 | 2019-2021 | |
| Exact Sciences Corporation | $44.63 | 2023-2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $43.05 | 2020-2021 | |
| Scynexis, INC. | $35.25 | 2021-2022 | |
| Shield Therapeutics INC | $33.31 | 2023 | Accrufer |
| Molnlycke Health Care US, LLC | $31.02 | 2023 | Mepilex Border Post-Op Ag, Avance |
| Medtronic, INC. | $19.06 | 2023 | Ligasure |
| Mycovia Pharmaceuticals, INC. | $18.92 | 2022 | |
| Meditrina | $16.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.71 | 2024 | Xifaxan |
| Amgen INC. | $14.83 | 2019 | |
| Novo Nordisk INC | $14.72 | 2020 | |
| Mission Pharmacal Company | $12.78 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Kolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.